News

News

Exvastat news post image

Further investment and three new appointments announced

Exvastat Ltd (“Exvastat”) receives further investment from Cambridge Innovation Capital and announce expansion of the team with three key new appointments

Read more
Exvastat news post image

First Patients Enter Clinical Trial of Impentri for COVID-19 ARDS

The Impentri IMI2 consortium are pleased to announce the first patients have entered their clinical trial to investigate the safety and efficacy of intravenous imatinib mesilate (Impentri) in subjects with Acute Respiratory Distress Syndrome induced by COVID-19

Read more
Exvastat news post image

CounterCOVID study shows imatinib significantly reduces mortality by 49% in patients with COVID-19

Results published on Friday 18th June by Exvastat’s collaborator in The Lancet Respiratory Medicine show that oral imatinib, currently used to treat cancers, reduces mortality by 49% in hospitalized COVID-19 patients. The results of the world-first trial, led by VUmc, Amsterdam, could signify another option in the management of COVID-19 to protect lives

Read more
Exvastat news post image

Exvastat commence work on EU grant awarded to initiate Phase II trial of IV imatinib for the treatment of COVID-19 pneumonia

18th May 2021: Cambridge, UK, Exvastat Limited, is pleased to announce it has commenced work on a prestigious European Innovation Council (EIC) accelerator grant, to support development of its innovative treatment, Impentri™ (intravenous imatinib) for the treatment of Acute Respiratory Distress Syndrome (ARDS) related to COVID-19.

Read more
Exvastat news post image

Appointment of Dr Julian Gilbert as Non-Executive Director

Read more
Exvastat news post image

CounterCOVID study reaches 50% recruitment milestone

Exvastat is pleased to announce the CounterCOVID trial of oral imatinib in Severe COVID-19 infection has reached the milestone of 50% recruitment into the 386-patient study.

The full details of the study protocol can be found here:

1 2
Next